Pharmacological and nonpharmacological prevention of atrial fibrillation after coronary artery bypass surgery

ABSTRACT

Atrial fibrillation [AF] is the most common complication of coronary artery bypass graft surgery [CABG]. The reported incidence of AF after CABG varies from 20% to 40%. Postoperative AF [POAF] is associated with increased incidence of hemodynamic instability, thromboembolic events, longer hospital stays, and increased health care costs. A variety of pharmacological and nonpharmacological strategies have been employed to prevent AF after CABG. Preoperative and postoperative beta blockers are recommended in all cardiac surgery patients as the first-line medication to prevent POAF. Sotalol and amiodarone are also effective and can be regarded as appropriate alternatives in high-risk patients. Corticosteroids and biatrial pacing may be considered in selected CABG patients but are associated with risk. Magnesium supplementation should be considered in patients with hypomagnesemia. There are no definitive data to support the treatment with nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, procainamide, and prop afenone, or anterior fat pad preservation to reduce POAF